Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05359562 · ClinicalTrials.gov registry record · NA
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
A NA study of OCD, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT05359562: Recruiting NA study of OCD, sponsored by University of Pennsylvania.
NCT05359562 is a NA study of OCD that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 120 participants, below the 811-participant average among 18 other OCD trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05359562, a NA study of OCD, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
Studies show that hormones affect the brain's fear extinction network, which is relevant for therapy involving exposure and response prevention (EX/RP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX/RP to women during different phases in their menstrual cycle to determine the effects of hormones on the fear extinction network and on their OCD symptoms.
Primary Outcome
Slope of change in brain activation (fMRI)
Conditions Studied
Interventions
- BEHAVIORAL Exposure & Response Prevention (EX/RP)
Study Locations (2)
New York
- New York State Psychiatric Institute - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2026-06 |
| Phase | NA |
What NCT05359562 shows while recruiting
NCT05359562 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 811-participant average among 18 other OCD trials with a reported enrollment target (85% lower).
The record links to 1 condition, with OCD appearing as the primary indexed condition, and to 1 intervention - of which Exposure & Response Prevention (EX/RP) is the first listed.
NCT05359562 reports a single indexed study location in New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05359562 about?
NCT05359562 is a clinical study titled "How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD". Studies show that hormones affect the brain's fear extinction network, which is relevant for therapy involving exposure and response prevention (EX/RP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX/RP to women during different ph...
What is the current status of trial NCT05359562?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2022-06-15. Estimated completion is 2026-06.
What conditions does trial NCT05359562 study?
This clinical trial studies the following conditions: OCD.
What interventions are being tested in trial NCT05359562?
The interventions under investigation include: Exposure & Response Prevention (EX/RP) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05359562?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05359562 being conducted?
This trial has 2 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OCD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05359562's enrollment target sits among peer trials
120 8th of 18 higher than 11 of 18 other OCD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other OCD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation for a Novel OCD Biomarker and Treatment
RECRUITING · NA
-
Personalized DBS for OCD Guided by Stereoencephalography Mapping
RECRUITING · NA
-
Neurostimulation Versus Therapy for Problems With Emotions
RECRUITING · NA
-
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
RECRUITING · NA
-
Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion
RECRUITING · NA
-
Accelerated TMS for Depression and OCD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI